SPA
CVAC

Sherbrooke Park Advisers’s CureVac CVAC Stock Holding History

Sherbrooke Park Advisers’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58,587
Closed -$199K – 971
2024
Q2 		$199K Buy
+58,587
New +$192K 0.03% 773

Other funds holding CVAC

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's CVAC Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of CureVac (CVAC) in Q3 2024, closing a stake of 58,587 shares — an estimated $199K sold.

Sherbrooke Park Advisers first reported a position in CVAC in Q2 2024 and held it in 1 quarter. The position peaked at $199K in Q2 2024. 81 funds tracked by Wall St. Rank hold CVAC as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining CureVac position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 58,587 CureVac shares in Q3 2024, an estimated $199K.
  • Sherbrooke Park Advisers first reported a position in CureVac in Q2 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's CureVac position peaked at $199K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held CureVac as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.